[{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences Initiates Natural History Study of Blood-Based Biomarkers in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences to Present Data and Moderate Session at AAIC 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal of the American Academy of Neurology Publishes ProMIS Neurosciences\u2019 Abstracts on Novel Antibody Candidates","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Fenway Sports Group","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences Re-Initiates Path to IND for PMN310 with Producer Cell Line Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.1 million","upfrontCash":"Undisclosed","newsHeadline":"ProMIS Neurosciences Inc. Announces Upsize of Previously Announced Public Offering of Units to US$17.5M","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Leede Jones Gable","pharmaFlowCategory":"D","amount":"$20.1 million","upfrontCash":"Undisclosed","newsHeadline":"ProMIS Neurosciences Closes Upsized US$20,125,000 Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promis Neurosciences\u2019 PMN310 Antibody Demonstrates Significant Cognitive Benefit In a Mouse Model of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences Presents Preclinical Results of its Experimental Alzheimer's Vaccine at the 2022 International AD\/PDTM Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences presents at the 2022 Neuro4D International Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences to Present at 2022 Alzheimer\u2019s Association International Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Fenway Sports Group","pharmaFlowCategory":"D","amount":"$7.4 million","upfrontCash":"Undisclosed","newsHeadline":"ProMIS Neurosciences Announces Closing of US $7.4 Million Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer\u2122s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Affinity Asset Advisors","pharmaFlowCategory":"D","amount":"$20.4 million","upfrontCash":"Undisclosed","newsHeadline":"ProMIS Neurosciences Announces $20.4 Million Private Placement Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"BTIG, LLC","pharmaFlowCategory":"D","amount":"$20.4 million","upfrontCash":"Undisclosed","newsHeadline":"ProMIS Neurosciences Closes $20.4 Million Private Placement Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimers Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by ProMIS Neurosciences
PMN400 is a lead vaccine candidate, targeting toxic alpha-synuclein protein clumps in cells. It is being evaluated in preclinical studies for the treatment of multiple system atrophy, parkinson’s disease and dementia with lewy bodies.
PMN310 is a novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ). It is under phase 1 clinical development for the treatment of Alzheimer's disease.
The proceeds will be used to advance the clinical development of ProMIS’ lead therapeutic candidate, PMN310, a monoclonal therapeutic antibody designed for the treatment of Alzheimer's disease (AD).
The net proceeds are expected to be used to advance the clinical development of ProMIS’ lead therapeutic candidate, PMN310, a monoclonal therapeutic antibody designed for the treatment of Alzheimer's disease by selectively targeting the toxic oligomers of amyloid-beta.
PMN310 is a novel monoclonal antibody which is designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) that are believed to be a major driver of alzheimer’s disease.
PMN310 is a novel monoclonal antibody which is designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) that are believed to be a major driver of alzheimer’s disease.
The proceeds from the offering will be used to advance ProMIS’ lead product candidate, PMN310, into a first-in-human study which the Company plans to commence in 2023, subject to FDA’s acceptance of an Investigational New Drug Application (IND).
PMN310, is a monoclonal antibody for Alzheimer’s disease created with a novel, proprietary method for generating and developing antibodies that can uniquely and precisely target toxic forms of otherwise normal proteins.
PMN310 is an antibody that binds to the neurotoxic amyloid beta aggregates, preventing additional amyloid beta monomers from adding to them. Therefore, PMN310 may potentially neutralize toxic aggregates and prevent neurodegeneration.
PMN310, is a monoclonal therapeutic antibody designed for treatment of Alzheimer’s disease. By selectively targeting toxic oligomers of amyloid-beta, showed a significant cognitive benefit in a widely recognized animal model of AD.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
